These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 34352021)
1. Correction: Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer. Stefanou DT; Bamias A; Episkopou H; Kyrtopoulos SA; Likka M; Kalampokas T; Photiou S; Gavalas N; Sfikakis PP; Dimopoulos MA; Souliotis VL PLoS One; 2021; 16(8):e0256051. PubMed ID: 34352021 [TBL] [Abstract][Full Text] [Related]
2. Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer. Stefanou DT; Bamias A; Episkopou H; Kyrtopoulos SA; Likka M; Kalampokas T; Photiou S; Gavalas N; Sfikakis PP; Dimopoulos MA; Souliotis VL PLoS One; 2015; 10(2):e0117654. PubMed ID: 25659114 [TBL] [Abstract][Full Text] [Related]
3. Correction: Aberrant DNA Methylation: Implications in Racial Health Disparity. Wang X; Ji P; Zhang Y; LaComb JF; Tian X; Li E; Williams JL PLoS One; 2016; 11(6):e0158251. PubMed ID: 27326861 [TBL] [Abstract][Full Text] [Related]
4. Correction: Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells. Siebenkäs C; Chiappinelli KB; Guzzetta AA; Sharma A; Jeschke J; Vatapalli R; Baylin SB; Ahuja N PLoS One; 2020; 15(12):e0243944. PubMed ID: 33301506 [TBL] [Abstract][Full Text] [Related]
5. Correction: Influence of platinum harmonized textile on neuromuscular, systemic and subjective recovery. Zinke F; Bakenecker P; Hahn D PLoS One; 2018; 13(1):e0191057. PubMed ID: 29315349 [TBL] [Abstract][Full Text] [Related]
6. Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers. Gschwantler-Kaulich D; Weingartshofer S; Rappaport-Fürhauser C; Zeillinger R; Pils D; Muhr D; Braicu EI; Kastner MT; Tan YY; Semmler L; Sehouli J; Singer CF PLoS One; 2018; 13(4):e0196142. PubMed ID: 29664962 [TBL] [Abstract][Full Text] [Related]
7. Correction: Blood type, ABO genetic variants, and ovarian cancer survival. PLOS ONE Staff PLoS One; 2017; 12(5):e0178965. PubMed ID: 28558036 [TBL] [Abstract][Full Text] [Related]
8. Correction: The hMLH1 -93G>A Polymorphism and Risk of Ovarian Cancer in the Chinese Population. Niu L; Li S; Liang H; Li H PLoS One; 2019; 14(5):e0218032. PubMed ID: 31150525 [TBL] [Abstract][Full Text] [Related]
9. Correction: Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells. Sharma A; Vatapalli R; Abdelfatah E; McMahon KW; Kerner Z; A Guzzetta A; Singh J; Zahnow C; Baylin SB; Yerram S; Hu Y; Azad N; Ahuja N PLoS One; 2020; 15(11):e0242750. PubMed ID: 33253231 [TBL] [Abstract][Full Text] [Related]
10. Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy. Luo S; Zhang Y; Yang Y; Zhu S; Liu W; Zhu J; Liang X; Jiang Z; Sun S; Hou X; Xiao Y; Li X Gynecol Oncol; 2020 Jul; 158(1):66-76. PubMed ID: 32402633 [TBL] [Abstract][Full Text] [Related]
11. Correction: Familial risks of ovarian cancer by age at diagnosis, proband type and histology. Zheng G; Yu H; Kanerva A; Försti A; Sundquist K; Hemminki K PLoS One; 2018; 13(10):e0206721. PubMed ID: 30365548 [TBL] [Abstract][Full Text] [Related]
12. Correction: Optical imaging of ovarian cancer using a matrix metalloproteinase-3-sensitive near-infrared fluorescent probe. Wang KH; Wang YM; Chiu LH; Chen TC; Tsai YH; Zuo CS; Chen KC; Changou CA; Lai WT PLoS One; 2018; 13(8):e0202610. PubMed ID: 30107000 [TBL] [Abstract][Full Text] [Related]
13. Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer Therapy. Dungl DA; Maginn EN; Stronach EA Front Oncol; 2015; 5():240. PubMed ID: 26579492 [TBL] [Abstract][Full Text] [Related]
14. Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer. Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S PLoS One; 2017; 12(10):e0186965. PubMed ID: 29045495 [TBL] [Abstract][Full Text] [Related]
15. Correction: Cytosolic Hsp70 as a biomarker to predict clinical outcome in patients with glioblastoma. Lämmer F; Delbridge C; Würstle S; Neff F; Meyer B; Schlegel J; Kessel KA; Schmid TE; Schilling D; Combs SE PLoS One; 2021; 16(3):e0248612. PubMed ID: 33705498 [TBL] [Abstract][Full Text] [Related]
16. Correction: Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq. Shih AJ; Menzin A; Whyte J; Lovecchio J; Liew A; Khalili H; Bhuiya T; Gregersen PK; Lee AT PLoS One; 2018; 13(12):e0208778. PubMed ID: 30513122 [TBL] [Abstract][Full Text] [Related]
17. Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer. Sharma Saha S; Gentles L; Bradbury A; Brecht D; Robinson R; O'Donnell R; Curtin NJ; Drew Y Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804647 [TBL] [Abstract][Full Text] [Related]
18. Correction: Role of mitochondrial DNA damage and dysfunction in veterans with Gulf War Illness. Chen Y; Meyer JN; Hill HZ; Lange G; Condon MR; Klein JC; Ndirangu D; Falvo MJ PLoS One; 2017; 12(10):e0186711. PubMed ID: 29036219 [TBL] [Abstract][Full Text] [Related]
19. Correction: Aberrant gene expression by Sertoli cells in infertile men with Sertoli cell-only syndrome. PLOS ONE Staff PLoS One; 2019; 14(8):e0221648. PubMed ID: 31430350 [TBL] [Abstract][Full Text] [Related]
20. Correction: Topical Application of Ochratoxin A Causes DNA Damage and Tumor Initiation in Mouse Skin. Kumar R; Ansari KM; Chaudhari BP; Dhawan A; Dwivedi PD; Jain SK; Das M PLoS One; 2018; 13(11):e0208284. PubMed ID: 30475895 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]